Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 29Triple Negative Breast Neoplasms 13Prostatic Neoplasms 13Ovarian Neoplasms 12Neoplasms 12Neoplasm Metastasis 9Fallopian Tube Neoplasms 6Leukemia, Myeloid, Acute 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Carcinoma, Renal Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Solid Tumor 1Sarcoma 1

Interventions

Filgrastim 20Etoposide 20Ifosfamide 19Cyclophosphamide 18Vincristine 13Radiotherapy 13Doxorubicin 13Peripheral Blood Stem Cell Transplantation 12Melphalan 12Carboplatin 10Busulfan 9Topotecan 8Temozolomide 8Magnetic Resonance Spectroscopy 8X-Rays 6Thiotepa 6Phantoms, Imaging 6Irinotecan 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 5trioctyl phosphine oxide 4Mesna 4Docetaxel 4Dactinomycin 4temsirolimus 3etoposide phosphate 3cixutumumab 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive, Peripheral × talazoparib × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

National Cancer Institute (NCI)

Phase 1/2 Completed
40 enrolled 32 charts
CNS

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡